Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer

Photodiagnosis Photodyn Ther. 2012 Mar;9(1):46-51. doi: 10.1016/j.pdpdt.2011.08.004. Epub 2011 Oct 1.

Abstract

Photodynamic therapy has the potential to become an effective alternate to surgery for the treatment of cancer. In recent years, there has been a focus on identifying more effective and less toxic photosentisizers for use in photodynamic therapy. The purpose of this study was to assess the effectiveness of mitoxantrone, a chemotherapeutic agent, as a photosensitizer for photodynamic therapy in the MCF-7 human breast cancer cell line. Cytotoxicity was evaluated for different concentrations of mitoxantrone, and photosensitivity was assessed using a non-coherent light source. The percentage of the cell survival after 24 h was investigated using the MTT assay. Overall, the results showed that mitoxantrone is a remarkably efficient photosensitizer that could mediate MCF-7 cell death at a low concentration (5 μM) with modest exposure to light. It is surprising to find that a chemotherapeutic agent can be an effective photosensitizer for PDT in vitro.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Breast Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Cell Survival
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Mitoxantrone / administration & dosage
  • Mitoxantrone / pharmacology*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / administration & dosage
  • Photosensitizing Agents / pharmacology*

Substances

  • Antineoplastic Agents
  • Photosensitizing Agents
  • Mitoxantrone